Identification of Phytomolecules as Isoform and Mutation specific PI3K-α inhibitor for protection against Breast Cancer using e-Pharmacophore modeling and Molecular dynamics simulations

Author:

Mili Ajay1,Birangal Sumit1,Giridhar Jyothi1,Nandakumar Krishnadas1,Lobo Richard1

Affiliation:

1. Manipal Academy of Higher Education

Abstract

Abstract

Mutations in PI3K-α contribute to a substantial proportion of breast cancer cases, particularly in HR+/HER2- subtypes. Inhibition of mutated PI3K-α will result in decrease in the progression of tumor growth. Nature has been a source of drug for numerous with compounds like Vincristine or Trabectedin, being use in cancer therapy. Therefore by using computational techniques like e-pharmacophore and molecular dynamics simulation, was used to identify natural compounds as an inhibitor of mutant and isoform specific PI3K-α. e-Pharmacophore was generated using Inavolisib drug (PDB:8EXV) and phase screening was done using Molport database for Natural compounds. After ligand docking, induced-fit docking, and ADMET analysis, Seven compounds were shortlisted for molecular dynamics simulation analysis. Out of those seven compounds, only three compounds, namely STOCK1N-85097, STOCK1N-85998, and STOCK1N-86060, show good RMSD, RMSF, Rg, SASA, PCA, FEL, and Total energy.

Publisher

Research Square Platform LLC

Reference22 articles.

1. World Health Organization. Breast cancer. (2023). Available at: https://www.who.int/news-room/fact-sheets/detail/breast-cancer. (Accessed: 18th December 2023)

2. Targeting the phosphoinositide 3-kinase pathway in cancer;Liu P;Nat. Rev. Drug Discov.,2009

3. Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy;Ihle NT;Mol. Cancer Ther.,2009

4. An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer;Stemke-Hale K;Cancer Res.,2008

5. PIK3CA Mutations Correlate with Hormone Receptors, Node Metastasis, and ERBB2, and Are Mutually Exclusive with PTEN Loss in Human Breast Carcinoma;Saal LH;Cancer Res.,2005

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3